MARKET OUTLOOK
Triton Market Research has concluded that the North America hyperphosphatemia drugs market is projected to grow at a CAGR of 15.66% in the estimated years 2019-2027.
Canada and the United States together form the hyperphosphatemia drugs market in the North America region.
The growing elderly population is a major driving factor for the growth of the hyperphosphatemia drugs market in Canada. The number of elderly citizens in the general population is progressively growing in the country. As the elderly population in Canada increases, the number of diseases such as hypertension, osteoporosis, etc., in them will also increase. Chronic kidney disease (CKD) is a significant public health issue. CKD is a crucial risk multiplier in patients with heart disease, diabetes, stroke and hypertension. Subsequently, the prevalence of CKD is quite high in elder citizens in Canada. Kidney disease can be described as a variety of diseases and disorders that affect the kidneys. Most of the diseases related to kidney affect the nephrons, which are the kidneys’ filtering units—and retard their ability of eliminating excess fluids and wastes. In the case of chronic kidney disease, an increase in the blood’s phosphorus levels occur due to improper excretions leading to hyperphosphatemia. Increasing cases for hyperphosphatemia in the elderly population is one of the most significant reasons contributing to the growth of the country’s hyperphosphatemia drugs market.
COMPETITIVE OUTLOOK
The biggest brands in the hyperphosphatemia drugs market include Sun Pharmaceutical Industries, Ltd., Shire, Cipla, Fresenius Medical Care, Fermenta Biotech, Ltd., Royal DSM N.V., Ultragenyx Pharmaceutical, Inc., Bio-Tech Pharmacal, Johnson and Johnson, Bruno Farmaceutici S.p.A., Keryx Biopharmaceuticals, Inc., Zeria Pharmaceutical, AMAG Pharmaceuticals, Roche Diagnostics Corporation, Sanofi and Pfizer, Inc.